Virtual Library

Start Your Search

Jing Zhang

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      130P - Relationship of clinicopathological characteristics, EGFR genotyping and prognosis in non-small cell lung cancer patients with malignant pleural effusion (ID 469)

      12:30 - 13:00  |  Presenting Author(s): Jing Zhang

      • Abstract
      • Slides


      To investigate the relationship of the clinical characteristics, EGFR genotyping and prognostic factors of malignant pleural effusion associated with non-small cell lung cancer (NSCLC).

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A total of 321 patients hospitalized in Guangxi Medical University Affiliated Tumor Hospital from November 2013 to December 2017 who were pathologically or cytologically confirmed NSCLC with malignant pleural effusion (MPE) were enrolled in the study. The information including clinical features at baseline, pleural effusion status, EGFR genomic alternation, treatment and prognosis for patients were retrospectively extracted and analyzed. The data were analyzed by SPSS 21.0 software. Chi-square test was used for comparison between groups, and Fisher’s exact probability method was used for correction. Survival curves were drawn by Kaplan-Meier method, and the differences between groups were compared by log-rank test. P < 0.05 was considered as statistical significance.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      There were significant differences in M staging, ECOG score and bone metastasis between patients with malignant pleural effusion at initial diagnosis and those with malignant pleural effusion at diseases progression (P < 0.05). The median overall survival for EGFR exon 19 deletion mutation, exon 21 L858R mutation and wild type in MPE patients were 21.8 months, 19.5 months and 11.6 months respectively (P = 0.005). The median overall survival for patients with EGFR sensitizing mutations treated with first- and second- generation EGFR-TKIs and those without TKI treatment was 21.9 months and 12.9 months respectively (P = 0.001). The median overall survival for wild type EGFR patients with simultaneous liver metastasis and non-liver metastasis was 5.8 months and 12.2 months respectively (P = 0.031).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Through comparing clinicopathological characteristics, EGFR genotyping and prognosis in MPE patients, those whose MPE were identified at the time of diagnosis are more frequently a higher incidence of ECOG score and bone metastasis, a longer OS in patients with EGFR mutation and treated with EGFR-TKI, and a significantly lower OS in patients with wild-type EGFR and liver metastasis.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.